The Case for Paternalism in Genetic Testing
By Laura Hercher,
Wired
| 01. 14. 2013
“So,” the journalist interviewing me asked, “you are for paternalism, then?”
Pause. I feel the linguistic walls closing in on me. Are you for paternalism? Are you against life? When did you stop beating your wife?
The case against paternalism in genetics is a cause célèbre among many scientists and science writers. The argument generally paints a picture of the medical professional as some sort of hybrid nanny-thug, protecting consenting adults from viewing their own genomes as though they were small children begging to play with knives, and at the same time fighting a bare-knuckle brawl with DTC companies to defend their turf as the only legitimate explicators of medical significance (because fortunes ride on the right to explain complex inheritance patterns and probability to the worried well. Please.).
The genome is not such a scary place and we have a right to our own genetic information. This case is made by many, including
Virginia Hughes at Slate and
Razib Khan at Discover and
Daniel MacArthur at Wired. These arguments are smart, well-written, ethically unassailable to a point –...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...